AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Discovery"
DOI: 10.1158/2159-8290.cd-22-0111
Abstract: Resistance of EGFR-mutant lung cancers to EGFR inhibitors can occur through engagement of mutation-prone DNA replication activated by GAS6 and AXL upregulation, and blocking this pathway can prevent resistance and offer new treatment strategies. read more here.
Keywords: egfr mutant; resistance offer; mutant lung; resistance ... See more keywords